在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

PD-1 Monoclonal Antibody

  • 中文名稱:
    PD-1鼠單克隆抗體
  • 貨號:
    CSB-MA619964A0m
  • 規格:
    ¥1320
  • 圖片:
    • Western Blot
      Positive WB detected in: 10μg 293 whole cell lysate transfected with PD-1, 25ng recombinant protein from E.coli, 25ng recombinant protein from Mammalian cell
      PD-1 antibody at 1:1000
      Secondary
      Goat polyclonal to mouse IgG at 1/50000 dilution
      Predicted band size: 72, 36 KDa
      Observed band size: 72, 36 KDa
      Exposure time:5min

  • 其他:

產品詳情

  • 產品描述:
    CUSABIO貨號:CSB-MA619964A0m PD-1單克隆抗體是針對免疫檢查點PD-1(程序性死亡受體1)研發的高特異性科研試劑,適用于探索腫瘤免疫逃逸機制及免疫治療相關研究。該抗體基于雜交瘤技術制備,能夠精準識別人類PD-1蛋白的表位,經過ELISA和Western Blot(WB)雙重平臺驗證,展現出優異的目標蛋白結合能力與批次穩定性,為科研人員提供可靠的數據重復性。PD-1作為T細胞功能的關鍵調控因子,在腫瘤微環境中的異常表達與多種惡性腫瘤的免疫抑制密切相關,本產品可助力研究人員深入解析PD-1/PD-L1信號通路在癌癥、自身免疫疾病中的分子機制。在應用場景中,該抗體適用于構建體外PD-1蛋白檢測體系、評估免疫檢查點抑制劑作用效果,以及開發新型腫瘤免疫聯合治療方案的基礎研究,為抗體藥物篩選和免疫治療靶點驗證提供關鍵實驗工具。通過優化的抗原親和純化工藝,確保抗體低交叉反應性,滿足免疫印跡、蛋白質互作分析等精細化實驗需求。
  • 產品名稱:
    Mouse anti-Homo sapiens (Human) PDCD1 Monoclonal antibody
  • Uniprot No.:
  • 基因名:
  • 別名:
    CD279 antibody; CD279 antigen antibody; hPD 1 antibody; hPD l antibody; hPD-1 antibody; hSLE1 antibody; PD 1 antibody; PD-1 antibody; PD1 antibody; PDCD 1 antibody; PDCD1 antibody; PDCD1_HUMAN antibody; Programmed cell death 1 antibody; Programmed cell death 1 protein antibody; Programmed cell death protein 1 antibody; Protein PD 1 antibody; Protein PD-1 antibody; SLEB2 antibody; Systemic lupus erythematosus susceptibility 2 antibody
  • 宿主:
    Mouse
  • 反應種屬:
    Human
  • 免疫原:
    Recombinant Human Programmed cell death protein 1 protein (21-170AA)
  • 免疫原種屬:
    Homo sapiens (Human)
  • 標記方式:
    Non-conjugated
  • 克隆類型:
    Monoclonal
  • 抗體亞型:
    IgG1
  • 純化方式:
    >95%, Protein G purified
  • 克隆號:
    2D8D11
  • 濃度:
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液:
    Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
  • 產品提供形式:
    Liquid
  • 應用范圍:
    ELISA, WB
  • 推薦稀釋比:
    Application Recommended Dilution
    WB 1:500-1:5000
  • Protocols:
  • 貨期:
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
  • 用途:
    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

  • 功能:
    Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self. Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2. Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation. Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta.; The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy.
  • 基因功能參考文獻:
    1. HLA-G, NRP1, and PD-1, may be involved in the immune response in psoriatic patients PMID: 29790686
    2. Proportions of naive CD4+ T cells were lower in young patients than in age-matched controls, and actually comparable to those in old patients and controls. This was accompanied with increased percentages of memory CD4+ T cells expressing HLA-DR, Ki-67, and PD-1 in young melanoma patients in comparison to the age-matched controls, but not in old patients. PMID: 29546435
    3. This meta-analysis demonstrates the PD-1 rs36084323 A > G polymorphism is associated with decreased cancer risk in Asian PMID: 30249505
    4. there is no significant association between PD1.3G/A - rs11568821 polymorphism and systemic lupus erythematosus or rheumatoid arthritis susceptibility in Southern Brazilian population. PMID: 27914594
    5. SLC18A1 might complement other biomarkers currently under study in relation to programmed cell death protein 1/programmed cell death protein ligand 1 inhibition PMID: 30194079
    6. Structural and functional analyses unexpectedly reveal an N-terminal loop outside the IgV domain of PD-1. This loop is not involved in recognition of PD-L1 but dominates binding to nivolumab, whereas N-glycosylation is not involved in binding at all. PMID: 28165004
    7. This finding suggested the potential application of PD-1 blockade in AML. The present work demonstrated an excellent synergistic tumour therapeutic effect of PD-1 blockade and CTL therapy compared with either treatment alone. PMID: 29962321
    8. High PD-1 expression is associated with Mycobacterium avium complex-induced lung disease. PMID: 28169347
    9. PD-1/PD-L1 expression is a frequent occurrence in poorly differentiated neuroendocrine carcinomas of the digestive system. PMID: 29037958
    10. Results indicated that high-level PD1 expression may be an important factor associated with the immune checkpoint pathway in liver cancer. PMID: 29620156
    11. These results suggest that the PD-1 genotype of the donor plays an important role for the development of acute GvHD after alloHSCT from HLA-identical sibling donors. PMID: 30019128
    12. We conclude that a subgroup of advanced disease ovarian cancer patients with high grade tumors, expressing PD-L1, may be prime candidates for immunotherapy targeting PD-1 signaling PMID: 29843813
    13. Both rs2227982 and rs2227981 polymorphisms were associated with T1 Diabetes (T1D) risk in East Asians, and rs2227982 also had a significant association with glycemic traits, which suggested PDCD1 gene polymorphisms might participate in facilitating T1D risk. [meta-analysis] PMID: 29774466
    14. PD.1 (-538G/A) gene polymorphism is associated with Colon Cancer Risk. PMID: 29580042
    15. The high-affinity PD-1 mutant could compete with the binding of antibodies specific to PD-L1 or PD-L2 on cancer cells. PMID: 29890018
    16. The G allele of rs36084323 of PDCD1 is associated with increased risk of advanced TNM staging of colorectal cancer. PMID: 29652996
    17. promoter methylation of CTLA4, PD-L1, PD-L2, and PD-1 in diffuse lower-grade gliomas (LGG) harboring isocitrate dehydrogenase (IDH) mutation, is reported. PMID: 29396294
    18. Unlike other multiple autoimmune disease associated genetic variants, there was no association between PDCD1 variants and Juvenile Idiopathic Arthritis PMID: 28056736
    19. Alteration of the PD-1/PD-L1 pathway can modulate Treg/Th17 balance in asthmatic children. PMID: 29874664
    20. The expression of PD1 on T cells was elevated in patients with rheumatoid arthritis and was correlated with the disease activity. PMID: 29257239
    21. High expression of programmed death-1 in sentinel lymph nodes is associated with breast cancer. PMID: 29193094
    22. We describe three cases of patients with mRCC treated with anti-PD-1 antibody therapy in combination with targeted therapy (bevacizumab), anti-cytotoxic T lymphocyte antigen 4 therapy (ipilimumab), or radiotherapy. PMID: 29146617
    23. anti-CTLA4/anti-PD-1/PD-L1 combinations versus anti-PD-1/PD-L1 monotherapy was selected as a factor independent of TMB for predicting better RR (77% vs. 21%; P = 0.004) and PFS (P = 0.024). Higher TMB predicts favorable outcome to PD-1/PD-L1 blockade across diverse tumors. PMID: 28835386
    24. The altered soluble (s)PD1 and sICOS serum levels in the different Hepatitis b (HBV) groups may reflect the dysregulation of T cell activation, and may be associated with the HBV pathological process. PMID: 28983583
    25. We found that PD-L1 expression was upregulated following TGF-beta induction; in contrast, it was downregulated by TGF-beta receptor-kinase inhibitors and the MET process. Furthermore, chemo-treatment increased TGF-beta expression and enhances PD-L1 expression via autocrine TGF-beta induced EMT. Analysis of clinical samples revealed a significant relationship between PD-L1 expression and EMT status PMID: 28849209
    26. this study demonstrated that PD-1 may involve in lymph nodes metastasis and promote the understanding of the mechanism of immunotherapies in the non-small cell lung cancer PMID: 28799818
    27. PD-L1 expression in melanoma tumor cells is lower than NSCLC or renal cell carcinoma cells. The higher response rate in melanoma patients treated with PD-1 inhibitors is likely related to PD-L1 in tumor-associated inflammatory cells. Further studies are warranted to validate the predictive role of inflammatory cell PD-L1 expression in melanoma and determine its biological significance PMID: 28223273
    28. Higher PRE PD-1(+) T cells in responders suggest active suppression of an engaged immune system that is disinhibited by anti-PD-1 therapies. Furthermore, immunoprofiling of EDT biopsies for increased PD-L1 expression and immune cell infiltration showed greater predictive utility than PRE biopsies and may allow better selection of patients most likely to benefit from anti-PD-1 therapies and warrants further evaluation PMID: 28512174
    29. PD-1 was overexpressed on CD8+ T-cells from patients with Obstructive Sleep Apnoea in a severity-dependent manner. PMID: 29051270
    30. The results show that the distinctive pathological features of papillary thyroid carcinomas (PTCs), including tumor-infiltrating lymphocytes (TILs), background chronic lymphocytic thyroiditis (CLT), female gender, psammoma bodies, and stromal calcification, are useful parameters for predicting PD-L1 or PD-1 expression. PMID: 28974264
    31. Our results did not show any association between PDCD1 SNPs and the development of juvenile idiopathic arthritis in an Iranian population PMID: 29307156
    32. High expressions of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) were associated with poor prognosis after surgery. PMID: 29848685
    33. Programmed death-1 polymorphism is associated with risk of esophagogastric junction adenocarcinoma. PMID: 28487496
    34. PD-1 was expressed in 26% of Ewing's sarcoma family of tumor cells and may have prognostic and therapeutic implications PMID: 29445891
    35. We now show that patients with low PD-L1 expression on myeloid cells have improved survival when treated with an antitumor vaccine, suggesting that PD-L1 expression on myeloid cells may be an important predictive biomarker in future clinical trials. Additionally, the combination of PD-1/PD-L1 inhibition and vaccination may increase the efficacy of this immunotherapeutic approach. PMID: 28193626
    36. Lower expression of PD-1 and PD-L1 was associated with better survival in patients who underwent surgery for the primary tumor and had multiple brain metastases PMID: 28201746
    37. PD-1/PD-L pathway inhibits Mycobacterium tuberculosis-specific CD4(+) T-cell functions and phagocytosis of macrophages in active tuberculosis. PMID: 27924827
    38. This study builds optimism that harmonization between assays may be possible, and that the three assays studied could potentially be used interchangeably to identify patients most likely to respond to anti-PD-1/PD-L1 immunotherapies, provided the appropriate clinically defined algorithm and agent are always linked. PMID: 28073845
    39. Results identified an overall low expression of PD-1 and PD-L1 in high-risk prostate cancer tissue. PMID: 28461179
    40. The biopsy tumor key protein measurements demonstrate substantial between-tumor variation in expression ratios of these proteins and suggest that programmed cell death 1 ligand 2 PD-L2 is present in some tumors at levels sufficient to contribute to programmed cell death-1 PD-1-dependent T-cell regulation and possibly to affect responses to PD-1- and programmed cell death 1 ligand 1 PD-L1-blocking drugs. PMID: 28546465
    41. Early phase clinical trials using PD-1 or PD-L1 inhibitors alone or in combination have shown objective tumor responses and durable long-term disease control, in heavily pre-treated patients, notably in the TN subtype. Blockade of PD-1 or PD-L1 shows impressive antitumor activity in some subsets of breast cancer patients PMID: 28799073
    42. Differential expression of immunological markers relating to the PD-1/PD-L1 pathway in blood can be used as potential diagnostic and prognostic markers in ovarian cancers. These data have implications for the development and trial of anti-PD-1/PD-L1 therapy in ovarian cancer. PMID: 27986748
    43. LAG-3+ iTILs are enriched in estrogen receptor-negative breast cancers and represent an independent favorable prognostic factor. In addition, a high proportion of PD-1/PD-L1+ tumors are co-infiltrated with LAG-3+ TILs. PMID: 29045526
    44. An IDO1 inhibitor, epacadostat also demonstrated promising activity in combination with the PD-1 checkpoint inhibitors in other solid tumors, including melanoma, urothelial carcinoma, renal cell carcinoma, and non-small cell lung cancer PMID: 28760910
    45. PD-L1 was positive in tumor cells in 2/13 cases, weak positive in 7/13, and negative in 4/13 cases, respectively PMID: 28807336
    46. we report the first case of immune microenvironment profiling and response to anti-PD-1 in a patient with Renal medullary carcinoma to our knowledge. This case suggests that anti-PD-1 based therapies may have clinical activity in Renal medullary carcinoma PMID: 28105368
    47. We present two cases of metastatic melanoma treated with nivolumab and pembrolizumab (anti PD-1). Both patients developed acute interstitial nephritis during immune checkpoint therapy PMID: 28105370
    48. the positive rate of PD-L2 did not show any differences between primary tumors and metastatic lymph nodes. In multivariate analysis, PD-L1 expression, PD-L2 expression, a low density of CD8(+) T cells in primary tumors, and PD-1 expression on CD8(+) T cells in primary tumors were associated with poor prognosis. PMID: 28754154
    49. Relative to controls, the expression of PD-1 and PD-L1 on peripheral blood and tumor infiltrating T cells increased with disease progression. Upregulation of expression promotes t-cells apoptosis in gastric adenocarcinoma. PMID: 29599324
    50. These data support the combinatorial approach of in situ suppression of the PD-L inhibitory checkpoints with DC-mediated IL15 transpresentation to promote antigen-specific T-cell responses and, ultimately, contribute to graft-versus-tumor immunity PMID: 28637876

    顯示更多

    收起更多

  • 相關疾病:
    Systemic lupus erythematosus 2 (SLEB2)
  • 亞細胞定位:
    Cell membrane; Single-pass type I membrane protein.
  • 數據庫鏈接:

    HGNC: 8760

    OMIM: 109100

    KEGG: hsa:5133

    STRING: 9606.ENSP00000335062

    UniGene: Hs.158297



主站蜘蛛池模板: 99久久国产露脸精品国产麻豆| 久久久久国产精品人妻aⅴ牛牛| 私人毛片免费高清影视院| 国产成人三级在线视频网站观看 | 伊人久久大香线蕉avapp下载| 无码人妻久久久一区二区三区| 无码一区二区三区老色鬼| 爽爽影院免费观看| 少妇的渴望hd高清在线播放| 伊人无码一区二区三区| 80s国产成年女人毛片| av无码精品一区二区三区四区| 最新精品露脸国产在线| 99蜜桃臀久久久欧美精品网站 | 久久精品人人槡人妻人| 大肉大捧一进一出好爽视频| 免费无码又爽又刺激软件下载直播| 日韩人妻无码一区二区三区综合 | 久久精品国产亚洲不av麻豆| 国产福利萌白酱精品tv一区| 奇米影视777四色狠狠| 色偷偷亚洲男人本色| 欧美人与zoxxxx另类| 无码人妻精品一区二区三区久久| 无码少妇一区二区三区芒果| 亚洲国产av精品一区二区蜜芽 | 国产成人免费ā片在线观看老同学| 亚洲一区二区三区日本久久九| 99久久婷婷国产一区二区| 亚洲欧美日韩二三区在线| 最爽无遮挡行房视频| 精品午夜福利1000在线观看| 人与动人物xxxx毛片| 国产成人午夜在线视频a站| 无码少妇一区二区浪潮免费| 国产av国片偷人妻麻豆| 乱妇乱女熟妇熟女网站| 51国产偷自视频区视频| 乱子伦农村xxxxbbb| 亚洲欧美综合一区二区三区| 国产在线一区二区av视频|